Valink Therapeutics is a London-based spinout of the University of Oxford, focused on the development of next generation antibody-based therapeutics. Valink identifies novel mechanism of action from known targets by incorporating multispecificity, multivalency and drug-conjugation into a single discovery process via our Universal Assembly Platform™. Valink’s research focus is on solid tumours poorly addressed by immunotherapy, in addition to select platform collaborations.